TITLE

Brand-name drug companies continue to break research and development spending promise

AUTHOR(S)
Vogel, Lauren
PUB. DATE
August 2010
SOURCE
CMAJ: Canadian Medical Association Journal;8/10/2010, Vol. 182 Issue 11, pE519
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the result of the annual report of the Patented Medicine Prices Review Board that indicates the continued failure of brand-name drug companies in Canada in fulfilling its promise regarding research and development spending. It states that Canadians are still paying the highest prices internationally for brand-name drugs despite low domestic investments. R&D President Russell Williams blames the economic recession and patient access gaps for the decline in R&D spending.
ACCESSION #
53068363

 

Related Articles

  • Brand-name drug companies fail to meet R&D commitments. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;8/15/2006, Vol. 175 Issue 4, p344 

    The article discusses the failure by brand-name drug companies to meet the research and development (R&D) commitments in Canada. A report by the Patented Medicine Prices Review Board (PMPRB) shows an increase in spending on brand-name drugs by Canadians, but relatively low company outlays for...

  • Canada's Pharmaceutical Price Control Paradox. Brett J. Skinner // Fraser Forum;Jun2005, p12 

    Presents a question and answer advisory about the practices of the drug price control in Canada. Role of the Patented Medicines Prices Review Board in enforcing drug price regulations; Applicability of federal drug price regulations to the legal class of drugs known as patented drugs; Influence...

  • A high price to pay for generic drugs in Canada.  // PharmacoEconomics & Outcomes News;8/12/2006, Issue 509, p11 

    The article focuses on the high price of generic drugs in Canada in 2005 compared to other countries, according to a report from the Canadian Patented Medicines Prices Review Board. Using market exchange rates, the report, based on data from IMS Health, compared prices for generics, non-patented...

  • R&D Spending Sees Dramatic Drop.  // Pharmaceutical Representative;Aug2011, Vol. 41 Issue 8, p8 

    The article reports on the decline of research and development (R&D) spending by the pharmaceutical industry.

  • The drugs don't work.  // New Statesman;4/18/2011, Vol. 140 Issue 5049, p14 

    The article presents the author's view that banks and financial institutions need to support pharmaceutical research that produces new drugs.

  • Keeping Up the Pace of Innovation. Siew, Adeline // Pharmaceutical Technology Europe;Jul2014, Vol. 26 Issue 27, p5 

    The article offers the author's insights about the success rate of the research and development (R&D) in the pharmaceutical industry and the things the industry should consider to boost innovation.

  • Branded Drug Makers in Canada Skimp on R&D.  // Chain Drug Review;7/19/2010, Vol. 32 Issue 12, p64 

    The article focuses on the study conducted by the Patented Medicine Prices Review Board (PMPRB) which found that research and development spending by branded drug companies in Canada has dropped to its lowest level in 20 years.

  • How to evaluate an outside R&D lab. Katz, Philip // DCI;Apr95, Vol. 156 Issue 4, p32 

    Discusses how to choose the right contract laboratory for pharmaceutical companies. Factors for considering the choice of contract laboratory; Need for the review of laboratory practices.

  • Contract Research Organizations Grow from the Core. Naude, Alice // Chemical Market Reporter;08/16/99, Vol. 256 Issue 7, pfr17 

    Discusses the significance of Contract Research Organizations (CRO) in the pharmaceutical industry. Importance of research and development in drug companies; Services rendered by CRO; Financial status of CRO.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics